Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 905
- Registration Number
- NCT01516879
- Locations
- 🇿🇦
Research Site, Bloemfontein, South Africa
AMG 761 in Adults With Asthma
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7
- Registration Number
- NCT01514981
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
AMG 172 First in Human Study in Patients With Kidney Cancer
Phase 1
Completed
- Conditions
- Renal Cell AdenocarcinomaClear Cell Renal Cell CarcinomaClear Cell Renal CarcinomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 37
- Registration Number
- NCT01497821
- Locations
- 🇩🇪
Research Site, Heidelberg, Germany
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Phase 3
Terminated
- Conditions
- Fallopian Tube CancerOvarian CancerPeritoneal Cancer
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1015
- Registration Number
- NCT01493505
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
Phase 1
Terminated
- Conditions
- Psoriasis
- Interventions
- Drug: AMG 557 or PLACEBO
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6
- Registration Number
- NCT01493518
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
Single Ascending Dose Trial in Patients With Type 2 Diabetes
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 47
- Registration Number
- NCT01492465
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT01464931
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Phase 2
Completed
- Conditions
- Type 2 Diabetes MellitusDiabetic Nephropathy
- Interventions
- Drug: PlaceboDrug: CCX140-B
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 332
- Registration Number
- NCT01447147
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Phase 3
Completed
- Conditions
- Idiopathic Thrombocytopenic PurpuraThrombocytopeniaThrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenic PurpuraImmune Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 62
- Registration Number
- NCT01444417
- Locations
- 🇨🇦
Research Site, Quebec City, Quebec, Canada
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Completed
- Conditions
- Colorectal CancerOvarian CancerAnemiaBreast CancerCancerLung CancerEndometrial CancerEsophageal CancerGastric CancerSolid Tumors
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1262
- Registration Number
- NCT01444456
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
© Copyright 2025. All Rights Reserved by MedPath